1-Butan-2-yl-3-[4-(3-methylanilino)pyridin-3-yl]sulfonylurea | 77281-87-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-Butan-2-yl-3-[4-(3-methylanilino)pyridin-3-yl]sulfonylurea
• CAS: 77281-87-9
• 化学式: C₁₇H₂₂N₄O₃S
• 分子量: 362.453
• InChiKey: FJWYVOBZDVHWKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  109
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-(3-甲基苯基)氨基吡啶-3-磺酰胺 在 4 A molecular sieve 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 8.0h， 生成 1-Butan-2-yl-3-[4-(3-methylanilino)pyridin-3-yl]sulfonylurea
  参考文献：
  名称：

  Delarge; Lapiere; De Ridder, European Journal of Medicinal Chemistry, 1981, vol. 16, # 1, p. 65 - 68

  摘要：

  DOI：

文献信息

• DELARGE J.; LAPIERE C. L.; RIDDER R. DE; GHYS A., EUR. J. MED. CHEM.-CHIM. THER., 1981, 16, NO 1, 65-68
  作者：DELARGE J.、 LAPIERE C. L.、 RIDDER R. DE、 GHYS A.

  DOI：——

  日期：——
• [EN] BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE<br/>[FR] ANALOGUES DE BUMÉTANIDE, FUROSÉMIDE, PIRÉTANIDE, AZOSÉMIDE ET TORSÉMIDE, ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION AFFÉRENTS
  申请人：NEUROTHERAPEUTICS PHARMA INC

  公开号：WO2010085352A2

  公开（公告）日：2010-07-29

  The present invention provides bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and methods for their use. All of these analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na+K+Cl- co-transporter or GABAA receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.
• Delarge; Lapiere; De Ridder, European Journal of Medicinal Chemistry, 1981, vol. 16, # 1, p. 65 - 68
  作者：Delarge、Lapiere、De Ridder、Ghys

  DOI：——

  日期：——